Barré Jean, Sabatier Jean-Marc, Annweiler Cédric
Department of Geriatric Medicine and Memory Clinic, Research Center on Autonomy and Longevity, University Hospital, Angers, France.
Aix-Marseille University, Institute of NeuroPhysiopathology, UMR 7051, Marseille, France.
Front Pharmacol. 2020 Sep 4;11:1344. doi: 10.3389/fphar.2020.01344. eCollection 2020.
With the lack of effective therapy, chemoprevention and vaccination, focusing on the immediate repurposing of existing drugs gives hope of curbing the pandemic. Interestingly, montelukast, a drug usually used in asthma, may be proposed as a potential adjuvant therapy in COVID-19. The aim of the present article was to review the properties of montelukast that could be beneficial in COVID-19. Ten experimentally supported properties were retrieved, either related to SARS-CoV-2 (antiviral properties, prevention of endotheliitis and of neurological disorders linked to SARS-CoV-2), and/or related to the host (improvement of atherogenic vascular inflammation, limitation of the ischemia/reperfusion phenomenon, improvement of respiratory symptoms), and/or related to serious COVID-19 outcomes (limitation of the cytokine storm, mitigation of acute respiratory distress syndrome), and/or related to tissue sequelae (antioxidant properties, anti-fibrosis effects). Based on gathered theoretical evidence, we argue that montelukast should be further tested to prevent and treat COVID-19 outcomes.
由于缺乏有效的治疗方法、化学预防措施和疫苗，专注于现有药物的直接重新利用为遏制这一流行病带来了希望。有趣的是，通常用于治疗哮喘的药物孟鲁司特，可能被提议作为新冠肺炎的一种潜在辅助治疗药物。本文的目的是综述孟鲁司特在新冠肺炎中可能有益的特性。我们检索到了十个有实验依据的特性，这些特性要么与严重急性呼吸综合征冠状病毒2（SARS-CoV-2）有关（抗病毒特性、预防与SARS-CoV-2相关的内皮炎症和神经紊乱），和/或与宿主有关（改善动脉粥样硬化性血管炎症、限制缺血/再灌注现象、改善呼吸道症状），和/或与严重的新冠肺炎结局有关（限制细胞因子风暴、减轻急性呼吸窘迫综合征），和/或与组织后遗症有关（抗氧化特性、抗纤维化作用）。基于收集到的理论证据，我们认为应该对孟鲁司特进行进一步测试，以预防和治疗新冠肺炎的结局。
